Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Minesapride beneficial to patients with irritable bowel syndrome

11 Apr 2020

Treatment with minesapride in patients with irritable bowel syndrome with constipation (IBS-C) is well tolerated and helps improve stool frequency, as well as abdominal and overall symptoms, according to the results of a phase II study from Japan.

Researchers randomized 171 patients with Rome III-defined IBS-C to receive minesapride (1, 4, 12, or 40 mg) or placebo once daily for 4 weeks. The modified intention-to-treat population included 171 patients (mean age, 38.5 years; 83.6 percent female). Mean disease duration was 10.7 years, and the mean weekly frequency of complete spontaneous bowel movements (CSBMs) was 0.6.

At week 4, the weekly frequency of CSBMs was greater in all minesapride groups than in the placebo group, with a significant difference between the latter and the 40-mg dose group (p=0.040). Moreover, the abdominal symptoms score markedly improved with minesapride 40 mg.

All treatment groups showed a reduction in the overall IBS severity index score from baseline to week 4, and the decrease was especially pronounced in the 12-mg and 40-mg dose vs placebo groups (p=0.048 and p<0.001, respectively).

Active treatment was well tolerated. Treatment-emergent adverse events (TEAEs) occurred in 55 percent of patients in the pooled minesapride groups and in 60 percent in the placebo group. The most common TEAE was diarrhoea (42.9 percent and 37.1 percent, respectively).

The present data underscore the utility of minesapride for treating patients with IBS-C, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).